title: CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis.
abstract: OBJECTIVE
  CD30 expression by bone marrow (BM) mast cells (MC) has been reported recently in systemic mastocytosis (SM) patients. The aim of this study was to investigate the potential diagnostic and prognostic value of CD30 expression in SM as assessed by multiparameter flow cytometry.
  
  
  RESULTS
  A total of 163 consecutive BM samples corresponding to 142 SM patients and 21 non-mastocytosis cases were studied. CD30 was positive in most SM patients (80%), but in only one non-mastocytosis case (4.8%). When combined with CD25, CD30 contributed to an improved accuracy over that of CD25 alone (98% versus 93%) mainly because most (eight of nine) of the well-differentiated SM (WDSM), who lacked CD25, were CD30(+). Similar levels of expression of CD30 were observed among all different subgroups of SM except mast cell leukaemia; among indolent SM (ISM) patients, no significant association was observed between the levels of CD30 expression and other clinical and biological features of the disease.
  
  
  CONCLUSIONS
  The increased expression of CD30 associated with absence of CD25 contributes to the diagnosis of WDSM and its distinction from other subtypes of SM. By contrast, CD30 expression did not contribute either to prognostic stratification of ISM or to the differential diagnosis between ISM and aggressive SM cases.
authors.affiliation: Instituto de Estudios de Mastocitosis de Castilla La Mancha, Toledo, Spain; Red Española de Mastocitosis, Toledo, Spain.
authors.forename: José M
authors.initials: JM
authors.lastname: Morgado
authors.forename: Omar
authors.initials: O
authors.lastname: Perbellini
authors.forename: Ryan C
authors.initials: RC
authors.lastname: Johnson
authors.forename: Cristina
authors.initials: C
authors.lastname: Teodósio
authors.forename: Almudena
authors.initials: A
authors.lastname: Matito
authors.forename: Iván
authors.initials: I
authors.lastname: Álvarez-Twose
authors.forename: Patrizia
authors.initials: P
authors.lastname: Bonadonna
authors.forename: Alberto
authors.initials: A
authors.lastname: Zamò
authors.forename: Maria
authors.initials: M
authors.lastname: Jara-Acevedo
authors.forename: Andrea
authors.initials: A
authors.lastname: Mayado
authors.forename: Andrés
authors.initials: A
authors.lastname: Garcia-Montero
authors.forename: Manuela
authors.initials: M
authors.lastname: Mollejo
authors.forename: Tracy I
authors.initials: TI
authors.lastname: George
authors.forename: Roberta
authors.initials: R
authors.lastname: Zanotti
authors.forename: Alberto
authors.initials: A
authors.lastname: Orfao
authors.forename: Luis
authors.initials: L
authors.lastname: Escribano
authors.forename: Laura
authors.initials: L
authors.lastname: Sánchez-Muñoz
mesh_terms: D001854:Bone Marrow Cells / Q000276:immunology* / Q000473:pathology*; D016022:Case-Control Studies; D003937:Diagnosis, Differential; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D053645:Interleukin-2 Receptor alpha Subunit / Q000378:metabolism; D017730:Ki-1 Antigen / Q000378:metabolism*; D008407:Mast Cells / Q000276:immunology* / Q000473:pathology*; D034721:Mastocytosis, Systemic / Q000175:diagnosis* / Q000235:genetics / Q000276:immunology*; D009154:Mutation; D011379:Prognosis; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics
chemical_list: C508017:IL2RA protein, human; D053645:Interleukin-2 Receptor alpha Subunit; D017730:Ki-1 Antigen; D019009:Proto-Oncogene Proteins c-kit
keywords: CD30; WHO; bone marrow; flow cytometry; mastocytosis